The medicine will cost between 58% and 75% less than the current cash price of branded insulin products for uninsured patients.

The news has sent shock waves through shares of drugstore chains and distributors.

Bogged down by the logistics of testing, employers are favoring lower-cost, easier-to-implement interventions like temperature checks.